RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates

• Status: Completed
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Babies aged 0 to 90 days with a suspected infection requiring treatment with vancomycin will be recruited. They will be randomised to receive vancomycin as an intermittent infusion (over 1 hour) or as a continuous infusion (over 24 hours). The hypothesis is that administering vancomycin as a continuous infusion will result in improved attainment of target concentrations in blood at steady state (when the drug is in equilibrium) compared to intermittent infusion.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Murdoch Childrens Research Institute
• Collaborators: Mercy Hospital for Women, Australia; Royal Children's Hospital; Royal Hospital For Women
• Treatments: Vancomycin

Criteria

Inclusion Criteria:

• Neonates in the neonatal unit with an infection requiring treatment with vancomycin as determined by the treating physician.

Exclusion Criteria:

• Infants with a corrected gestational age < 25 weeks.

• Allergy to vancomycin or other glycopeptide antibiotic

• Vancomycin administered within the previous 72 hours

• Renal impairment

• Prior enrolment in the study

• Need for drug that is incompatible with vancomycin (if no other IV line is available)